362471-95-2

Upstream product

• 362471-87-2 2-{(2S)-3-[(2R,6R)-6-(2-[(tert)-butyl{dimethyl}silyloxy]ethyl)-3,6-dihydro-2H-pyran-2-yl]-2-methylpropyl}prop-2-en-1-ol 
• 5949-05-3 (S)-Citronellal 
• 362471-85-0 acetic acid 2-(3-{6-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-3,6-dihydro-2H-pyran-2-yl}-2-methyl-propyl)-allyl ester 
• 676474-20-7 acetic acid 4-methyl-2-methylene-5-[6-(2-oxo-ethyl)-3,6-dihydro-2H-pyran-2-yl]-pentyl ester 
• 362471-89-4 (2S,4S)-1-{[tert-Butyl(diphenyl)silyl]oxy}-4,8-dimethylnon-7-en-2-ol 
• 362471-91-8 ethyl (5R,7S)-5-hydroxy-7,11-dimethyldodec-10-en-2-ynoate 
• 362471-93-0 2-{(2S)-3-[(2R)-6-ethoxy-3,6-dihydro-2H-pyran-2-yl]-2-methylpropyl}prop-2-enyl acetate 
• 362471-83-8 2-{(2S)-3-[(2R)-6-ethoxy-3,6-dihydro-2H-pyran-2-yl]-2-methylpropyl}prop-2-en-1-ol 
• 362471-77-0 (6R)-[(2S)-2,6-dimethylhept-5-enyl]-5,6-dihydro-2H-pyran-2-one 
• 362471-81-6 2-{(2S)-2-methyl-3-[(2R)-6-oxo-3,6-dihydro-2H-pyran-2-yl]propyl}propenal 
• 362471-73-6 (2S,4S)-4,8-dimethylnon-7-ene-1,2-diol 
• 362471-79-2 (4S)-4-methyl-5-[(2R)-6-oxo-3,6-dihydro-2H-pyran-2-yl]pentanal 
• 362471-75-8 (2R)-2-[(2S)-2,6-Dimethylhept-5-enyl]oxirane 
• 362471-71-4 (2R,S)-2-[(2S)-2,6-dimethylhept-5-enyl]oxirane 

Downstream Products

• 676474-18-3 6,11-bis-(tert-butyl-dimethyl-silanyloxy)-10-(4-methoxy-benzyloxy)-2-methyl-13-(4-methyl-3,6-dihydro-2H-pyran-2-yl)-4-methylene-1-(6-prop-2-ynyl-3,6-dihydro-2H-pyran-2-yl)-trideca-7,12-diene 
• 849362-07-8 4-{6-[6-(tert-butyl-dimethyl-silanyloxy)-11-methoxy-10-(4-methoxy-benzyloxy)-2-methyl-13-(4-methyl-3,6-dihydro-2H-pyran-2-yl)-4-methylene-trideca-7,12-dienyl]-5,6-dihydro-2H-pyran-2-yl}-but-2-ynoic acid 
• 849362-06-7 tert-butyl-{6-methoxy-5-(4-methoxy-benzyloxy)-8-(4-methyl-3,6-dihydro-2H-pyran-2-yl)-1-[4-methyl-2-methylene-5-(6-prop-2-ynyl-3,6-dihydro-2H-pyran-2-yl)-pentyl]-octa-2,7-dienyloxy}-dimethyl-silane 
• 676474-17-2 11-(tert-butyl-dimethyl-silanyloxy)-10-(4-methoxy-benzyloxy)-2-methyl-13-(4-methyl-3,6-dihydro-2H-pyran-2-yl)-4-methylene-1-(6-prop-2-ynyl-3,6-dihydro-2H-pyran-2-yl)-trideca-7,12-dien-6-ol 
• 849362-05-6 (7E,12E)-(2S,10S,11S)-11-Methoxy-10-(4-methoxy-benzyloxy)-2-methyl-13-((S)-4-methyl-3,6-dihydro-2H-pyran-2-yl)-4-methylene-1-((2R,6R)-6-prop-2-ynyl-3,6-dihydro-2H-pyran-2-yl)-trideca-7,12-dien-6-ol 
• 676473-70-4 acetic acid 5-[6-(3,3-dibromo-allyl)-3,6-dihydro-2H-pyran-2-yl]-4-methyl-2-methylene-pentyl ester 
• 676474-11-6 Acetic acid (S)-4-methyl-2-methylene-5-((2R,6R)-6-prop-2-ynyl-3,6-dihydro-2H-pyran-2-yl)-pentyl ester 
• 115268-43-4 laulimalide 

Relevant academic research and scientific papers

Concise synthesis of the C3-C14-fragment of the antitumor agent laulimalide. Application of Jacobsen's HKR reaction

Bromide 3, which represents an appropriately functionalized C3-C14-fragment of the antitumor agent laulimalide (1) has been synthesized from (-)-citronellal (4) in an overall yield of ca. 17% (12 isolated intermediates). At a very early stage, the synthes

LAULIMALIDE ANALOGS AND USES THEREOF

The present invention provides compounds having formula 1: (I) and pharmaceutically acceptable derivatives thereof, wherein R1-R10, q, t, X0, X1, A, B, D, E, G, J, K, L, M and Z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders associated with cellular hyperproliferation.

Synthesis and biological evaluation of (-)-laulimalide analogues

Analogues of the marine natural product (-)-laulimalide were prepared by total synthesis and evaluated in vitro for anticancer activity.